VERAXA advances VXA-222 antibody-drug program
VERAXA Biotech (NASDAQ:VRXA) announced that its VXA-222 bispecific antibody-drug conjugate programme has reached a technical milestone and advanced into the next phase of its collaboration with OmniAb (NASDAQ:OABI).










